Trump Orders Psychedelic Review, $50M Funding

**President Trump signed an executive order to fast‑track federal review of psychedelic drugs such as ibogaine and directed at least $50 million to state programs for serious mental illness.** The order follows a public endorsement from podcaster Joe Rogan, who said Trump replied to his ibogaine information with a text urging FDA approval.

Psychedelics remain Schedule I substances under federal law, which severely restricts research and clinical use. Ibogaine comes from the root bark of a West African shrub and has been used in Bwiti spiritual ceremonies.

Some veteran groups claim ibogaine alleviates PTSD symptoms. In recent years, lawmakers from both parties have called for more study of psychedelics for depression, anxiety, and substance use disorders, though most existing data come from small open‑label or observational studies.

The executive order instructs the Department of Health and Human Services to allocate no less than $50 million to states that have enacted or are developing psychedelic therapy programs for serious mental illness.

It also directs HHS to accelerate the federal review process for substances like ibogaine, aiming to reduce regulatory barriers.

During the signing ceremony, Joe Rogan recalled texting Trump about ibogaine and receiving the reply, "Sounds great. Do you want FDA approval? Let's do it."

Clinical evidence on ibogaine is still preliminary; a 2021 open‑label cohort of 27 veterans with PTSD reported lower symptom scores, but without a control group the observed changes cannot be attributed to the drug.

A 2022 randomized controlled trial of psilocybin for major depression involving 59 participants showed a statistically significant improvement over placebo, demonstrating how rigorous designs can establish efficacy.

Because most psychedelic research to date is observational or small‑scale, readers should treat any therapeutic claims as tentative and discuss options with a licensed clinician. Practically, the new federal funding may enable more state‑level clinics to offer supervised psychedelic‑assisted therapy, yet ibogaine remains illegal outside approved research settings and carries risks such as QT‑prolongation that necessitate cardiac monitoring.

Watch for the FDA’s upcoming national priority vouchers for three psychedelics and the launch of the first‑ever U.S. human trials of ibogaine, which will provide clearer data on safety and therapeutic potential.